Insmed, Inc. (NASDAQ:INSM) Stock Has Consensus Target Price of $196.52 According to Brokerages

Key Points

• Analysts are broadly bullish: Insmed has a “Moderate Buy” consensus from 26 analysts, with 23 buy and one strong-buy rating; the average 12-month price target is $196.52.
• Revenue surged, but earnings missed: Quarterly revenue rose 268.4% year over year to $524.43 million, beating estimates, while EPS of -$0.46 fell short of the -$0.38 consensus.
• Insmed shares opened at $121.16, well below their 12-month high of $212.75. A company director also sold 25,000 shares for $3.1 million.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-six analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twenty-three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $196.52.

Several brokerages have commented on INSM. BMO Capital Markets reiterated an "outperform" rating on shares of Insmed in a research report on Tuesday, October 6th. UBS Group restated a "buy" rating on shares of Insmed in a research report on Thursday, October 8th. Raymond James Financial set a $173.00 price objective on Insmed in a research note on Tuesday, October 20th. Wells Fargo & Company upped their price objective on Insmed from $161.00 to $169.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Barclays cut their target price on Insmed from $237.00 to $207.00 and set an "overweight" rating on the stock in a research note on Wednesday, September 30th.

Insider Activity at Insmed

In related news, Director David Brennan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the sale, the director directly owned 39,238 shares in the company, valued at $4,865,512. This trade represents a 38.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Sei Investments Co. raised its holdings in Insmed by 56.8% in the first quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company's stock worth $228,239,000 after purchasing an additional 505,624 shares during the period. Pictet Asset Management Holding SA grew its holdings in shares of Insmed by 44.0% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company's stock valued at $200,845,000 after buying an additional 537,188 shares during the period. NWI Management LP grew its holdings in shares of Insmed by 2.6% in the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company's stock valued at $165,809,000 after buying an additional 25,540 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Insmed by 480.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company's stock valued at $144,591,000 after buying an additional 1,048,518 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Insmed in the 2nd quarter valued at $139,966,000.

Insmed Price Performance

Shares of INSM stock opened at $121.16 on Friday. The firm has a market cap of $26.58 billion, a price-to-earnings ratio of -42.96 and a beta of 0.83. Insmed has a 12 month low of $90.39 and a 12 month high of $212.75. The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77. The stock has a 50-day moving average price of $110.82 and a 200 day moving average price of $123.37.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The business had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. During the same quarter in the previous year, the company posted ($1.75) earnings per share. The business's revenue for the quarter was up 268.4% on a year-over-year basis. Research analysts expect that Insmed will post -1.86 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.